News
-
-
PRESS RELEASE
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma enrolls first patient in SKNJCT-004 phase 2 clinical study for non-invasive BCC treatment in UAE with Cleveland Clinic Abu Dhabi as lead investigator -
-
-
-
-
-
PRESS RELEASE
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
FDA agrees to 505(b)(2) pathway for Medicus Pharma's Skinject D-MNA to treat BCC, positive Type C meeting feedback, SKNJCT-003 patient recruitment aims, EOP2 request in Q1 2026 -
-
